BridgeBio holder plans 20,000‑share Rule 144 sale

BridgeBio Pharma (symbol BBIO) filed a notice of proposed stock sale under Rule 144.

Rhea-AI Filing Summary

BridgeBio Pharma (symbol BBIO) filed a notice of proposed stock sale under Rule 144. The filing covers up to 20,000 shares of common stock, with an aggregate market value of $1,505,000, to be sold through Morgan Stanley Smith Barney on NASDAQ around February 17, 2026.

The shares were acquired the same day through a cash exercise of stock options for 20,000 shares. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

Insights

Equity markets analyst

Routine Rule 144 filing for a 20,000‑share planned sale, neutral impact.

The notice describes a planned sale of 20,000 BBIO common shares with an aggregate market value of $1,505,000. The shares will be sold on NASDAQ through Morgan Stanley Smith Barney. This is a standard Rule 144 process for resales of restricted or control securities.

The same 20,000 shares were obtained via cash exercise of stock options on 02/17/2026, so the issuer receives option exercise proceeds while the selling holder may receive sale proceeds. The representation that no undisclosed material adverse information is known is a typical Rule 144 certification, so the event looks administrative rather than thesis-changing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BBIO Rule 144 filing disclose about planned share sales?

The filing discloses a planned sale of up to 20,000 shares of BridgeBio Pharma common stock. These shares, valued in total at about $1,505,000, are expected to be sold on the NASDAQ through Morgan Stanley Smith Barney under Rule 144.

At what price and market value are BBIO shares listed in this Rule 144 notice?

The notice lists 20,000 BBIO common shares with an aggregate market value of $1,505,000. This implies the filer used the prevailing market prices to compute total value when preparing the form for the intended NASDAQ sale.

How were the BBIO shares in this Rule 144 filing acquired?

The 20,000 BBIO shares were acquired via a cash exercise of stock options on 02/17/2026 from the issuer. The filing states that the nature of payment was cash, indicating a standard option exercise transaction before the planned resale.

Which broker is handling the BBIO Rule 144 share sale?

The planned sale of BBIO common stock will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. Their listed office for this transaction is at 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are to be sold on NASDAQ.

What representation does the seller make in the BBIO Rule 144 notice?

The seller represents that they do not know any material adverse information about BridgeBio Pharma’s current or prospective operations that has not been publicly disclosed. This statement is part of the standard certification language included in Rule 144 notices.

Does the BBIO Rule 144 filing mention recent sales in the past three months?

The form includes a section requesting information on all securities of the issuer sold during the past three months. In the provided content, only the planned 20,000‑share transaction and its details are shown, without additional completed sales information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:40 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001337801
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BridgeBio Pharma, Inc.
SEC File Number	001-38959
Address of Issuer	3160 PORTER DRIVE SUITE 250 Palo Alto CALIFORNIA 94304
Phone	6503919740
Name of Person for Whose Account the Securities are To Be Sold	RANDAL SCOTT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	20000	1505000.00	192708813	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2026	Exercise of Stock Options	Issuer			20000	02/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	02/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Randal W Scott
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)